Novartis chief Jimenez touts two top PhIII drug prospects
Novartis CEO Joe Jimenez has been busy giving interviews at Davos this week.
In a sit-down with Reuters the Basel-based exec noted that Trump’s tax policies could help set the stage for building new manufacturing facilities in the US. And he also tapped two late-stage drugs as among his favorites in the pipeline.
Those two favorites are CTL-019, the pioneering CAR-T that Novartis is steering to a near-term application at the FDA, and BAF-312 for secondary progressive multiple sclerosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
